{"analyses":[{"ciLowerLimit":"0.617","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.835","estimateComment":"Hazard ratio of Albumin bound paclitaxel + gemcitabine/gemcitabine alone. The associated hazard ratio and two-sided 95% confidence interval were estimated using a stratified Cox proportional hazard model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","pValueComment":"P-value was based on a stratified log-rank test stratified by randomization strata of geographic region (North America versus Others), Karnofsky performance score (70 to 80 versus 90 to 100), and presence of liver metastasis","paramType":"Hazard Ratio (HR)","paramValue":"0.72","statisticalMethod":"Stratified Log-rank Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.89","upperLimit":"9.53","value":"8.5"},{"groupId":"OG001","lowerLimit":"6.01","upperLimit":"7.23","value":"6.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"431"},{"groupId":"OG001","value":"430"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the date of randomization to the date of death from all causes. Participants who did not die were censored at the last known time the participant was alive. Patient survival was summarized using Kaplan-Meier methods.","dispersionType":"95% Confidence Interval","groups":[{"description":"Albumin-bound paclitaxel (ABI-007)/Gemcitabine: ABI-007 125 mg/m\\^2 administered intravenously (IV) in combination with Gemcitabine 1000 mg/m\\^2 IV weekly for 3 weeks on Days 1, 8, and 15 followed by one week of rest","id":"OG000","title":"Albumin-bound Paclitaxel (ABI-007)/Gemcitabine"},{"description":"Gemcitabine 1000 mg/m\\^2 administered IV weekly for 7 weeks through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks on Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward)","id":"OG001","title":"Gemcitabine"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat population (ITT population) consisted of all randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization to death; until the data cut off 17 Sept 2012. The maximum time in follow up was 37 months.","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}